Objective: Glycated hemoglobin (HbA 1c ) may not accurately reflect the level of glycemia in conditions of altered erythrocyte turnover. Hypothyroidism is one condition associated with sluggish erythropoesis. To assess changes in HbA 1c , independent of changes in plasma glucose after initiation of thyroxine replacement in patients with overt hypothyroidism. Materials and methods: In this prospective longitudinal study carried out in a tertiary care centre, adult non-diabetic patients with overt hypothyroidism recruited between March 2012 to August 2013 were rendered euthyroid on thyroxine. They underwent testing for hemoglobin, HbA 1c , reticulocyte count, thyroxine, thyrotropin and a standard oral glucose tolerance test, both before and at 3 months after restoration to the euthyroid state. Main outcome assessed was the change in HbA 1c independent of the change in glucose parameters. Results: Thirty eight patients (35 female and 3 male) aged 37.8 ± 10.2 years with overt hypothyroidism (thyroxine 12.6 ± 13.4 ng/mL and thyrotropin -98.1 ± 63.7 µIU/mL respectively) were recruited. While HbA 1c fell from 5.8 ± 0.7% to 5.6 ± 0.5% (p = 0.009) at 3 months following the correction of hypothyroidism, there were no changes in the fasting and the 2 hr post oral glucose tolerance test glucose (p = 0.67 and 0.56 respectively). The number of patients with dysglycemia diagnosed by HbA 1c (i.e HbA 1c ≥ 5.7%) fell from 25 (65.78%) to 17 (44.7%) after treatment (p = 0.008). There were 7 (18.4%) patients with HbA 1c ≥ 6.5% at baseline, but this fell to just 4 (10.5%) (p < 0.001) after 3 months of euthyroidism. Conclusion: HbA 1c is not a reliable diagnostic test for diabetes in the presence of hypothyroidism. Arch Endocrinol Metab. 2015;59(6):495-500
INTRODUCTION
T he American Diabetic Association has recently approved the use of glycated hemoglobin (HbA 1c ) as a screening as well as diagnostic test for diabetes mellitus. A value ≥ 5.7% but < 6.5% was considered to represent pre-diabetes, while a value ≥ 6.5% was considered diagnostic of diabetes mellitus (1, 2) .
The glycated hemoglobin represents the fraction of hemoglobin that undergoes non-enzymatic glycation over the circulatory life span of the erythrocytes (usually 120 days) (3, 4) . It not only depends on the ambient level of glycemia over the preceeding 2-3 months (5), but also on the average period of exposure of the circulatory red blood cells (RBCs) to this glycemia i.e on the erythrocyte turnover in circulation (3, 5) . Conditions which are associated with a low RBC turnover, with a predominance of older cells (and a paucity of younger RBCs and reticulocytes) in circulation are associated with a falsely elevated HbA 1c . Proven examples include iron (6, 7) and vitamin B12 deficiency (6) , and renal failure (8) .
Among the hypoplastic anaemias, an important and common etiological factor is hypothyroidism (9, 10) . In response to the diminished metabolism and the reduced requirements for oxygen, there is reduced erythropoietin production from the proximal renal tubules (11) .
It is conceivable that this reduced erythropoiesis may result in a false elevation of HbA 1c (12) resulting in some cases in an erroneous diagnosis of pre diabetes or diabetes. We planned to assess changes in patient categorization between euglycemia, prediabetes and diabetes mellitus based on HbA 1c levels, resulting from thyroxine replacement to hypothyroid patients-an aspect not studied before. 
MATERIALS AND METHODS

Study design
The study was a prospective study conducted in the Department of Endocrinology and Metabolism at a tertiary care centre in India. The study period was from March 2012 to August 2013. Patients aged more than 20 years with a biochemical diagnosis of overt hypothyroidism (i.e TSH > 15 µIU/mL and T 4 < 55 ng/ mL) were recruited for the study. Patients satisfying glucose based criteria for diabetes mellitus as recommended by the American Diabetes Association (ADA) (13) in 2009, were excluded from the study. Suspected or known case of chronic kidney disease, abnormal haemoglobinopathy, haemolytic disorder, reticulocytosis (reticulocytes > 2.5% of all erythrocytes), bone marrow disorders like aplastic anaemia, myelodysplastic syndrome or recent (< 3 months) blood transfusion were excluded from the study.
Written informed consent was obtained from all patients for participation in the study. The study was cleared by the Institutional Ethics Committee. Weight and height of recruited patients was recorded. Blood samples of the enrolled patients were obtained in the morning between 0800-0900 hr after an overnight fast for fasting plasma glucose (FPG), serum creatinine, hemoglobin (Hb), HbA 1c , reticulocyte count and serum T 4 BSA. Haemoglobin was estimated on an automated haematology analyzer by colorimetric method (Shenzhen Mindray Biomedical Electronics Co Ltd, Hamburg 20537, Germany). Reticulocytes were counted by a trained observer after staining of peripheral blood smear with a supravital stain (new methylene blue) and expressed as a percentage of total red blood cells.
Patients were then started on thyroxin supplements for 3 months. The dose of the drug was increased periodically (every 4-6 weeks) step wise, based on TSH estimations till the patients were rendered euthyroid, i.e had TSH between 0.5-5 µIU/ml. Once the patient had been restored to the euthyroid state, the patient was allowed to continue the same dose of thyroxin and recalled after three months. After three months of documentation of euthyroidism, the following investigations were repeated as before: serum T 4 and TSH, fasting plasma glucose and post glucose load 2 hr plasma glucose, HbA 1c , haemoglobin and reticulocyte percentage. Reticulocyte percentage was determined by the same expert, who performed the same determination at baseline.
Sample size
The study was planned to detect change in HbA 1c before and after restoration of the euthyroid state with a power of 80% and a significance level at a p < 0.05. The standard deviation of HbA 1c (σ) in the normal population, as represented by the normal healthy control subjects in the study by Kim and cols. (12) was 0.31%. In that study the correction of hypothyroidism lead to fall of 0.2% in the HbA 1c . Expecting to demonstrate a similar or greater change in our patients, the minimal sample size required to demonstrate a change (δ) of 0.2% in the HbA 1c was obtained as given below (15):
where Z α (coefficient of α error) assumes a value of 1.96 and Z 1-β (coefficient of β error) takes a value of 0.8416 for a statistical power of 80% and at a significance level of p < 0.05 for comparison of means of HbA 1c before and after the correction of hypothyroidism by a 2 tailed paired t test. Substituting the values of σ and δ as mentioned above the required sample size was 37.
Statistical analysis
Data was recorded on a pre designed proforma and managed using Microsoft Excel 2007 (Microsoft Corp, Redmond, WA). Continuous variables were compared with same parameters measured 3 months after the restoration of euthyroidism using two tailed paired t test with a p value of < 0.05 being considered as significant. Baseline proportions were compared with those measured 3 months after the restoration of euthyroidism by the McNemar χ 2 test. Statistical software SPSS version 15 (SSPS Inc., Chicago, IL) was used for statistical analysis.
RESULTS
Baseline clinical features
A total of 38 consecutive patients with confirmed overt hypothyroidism (i.e TSH > 15 µIU/ml and T 4 < 55 ng/mL) were recruited for the study over a period of one and a half years. Baseline patient characteristics are given below in table 1.
Effect of thyroxine replacement
Patients were re-evaluated 3 months after restoration to the euthyroid state. The recorded changes are given in table 2.
Following correction of T4 and TSH to 105.7 ± 36.9 ng/mL and 2.5 ± 3.5 µIU/mL respectively, there was a reduction in the mean body weight by 3.5 kg (p = 0.004). Likewise, there was improvement in the hemoglobin from 11.7 ± 1.9 gm/dL to 12.1 ± 1.6 gm/dL (p = 0.044). This was accompanied by a rise in the reticulocyte percentage from 0.9 ± 0.6% to 1.2 ± 0.7% (p = 0.046). No patient fulfilled glucose criteria for diabetes at baseline, due to exclusion of such patients at baseline. Nevertheless there were 7 (18.4%) patients with HbA 1c ≥ 6.5% at baseline (representing false diagnosis of DM by HbA 1c ), but this fell to just 4 (10.5%) (p < 0.001) after 3 months of euthyroidism.
Changes in glycemic indices
On multiple linear regression analysis, none of the following parameters: namely the change in the hemoglobin, reticulocyte percentage, body mass index or the fasting or post OGTT plasma glucose were independently predictive (p > 0.05) of the change in the HbA 1c between the baseline and final follow up.
DISCUSSION
Recently the American Diabetes Association has recommended the use of HbA 1c for the diagnosis of diabetes mellitus (2) . However there has always been concern about the use of HbA 1c in certain conditions, where this does not accurately reflect the level of glycemia. Disorders associated with changes in the RBC turnover can affect the HbA 1c independently from the glycemic status, by altering the relative proportion of young and old RBCs in circulation i.e the average age of the RBCs (3, 4) . Thus disorders with reduced RBC turnover and a preponderance of older RBCs in circulation, like iron deficiency (6,7), vitamin B12 deficiency (6), or renal failure (8) , can have a falsely elevated HbA 1c .
Among the latter group of disorders, one which is widely prevalent is hypothyroidism. Indeed studies in our country show that overt hypothyroidism is found in 3.9% to 10.95% of the general population (16, 17) . These prevalence rates are much higher than that found in the Western population, where the prevalence of overt hypothyroidism is only 0.3-0.4% of the adult population (18, 19) . Thus, India seems to be having a much higher burden of hypothyroidism. Thus any impact of hypothyroidism on HbA 1c is likely to be a bigger issue in India than in the Western countries.
We enrolled newly diagnosed patients with overt hypothyroidism. Those patients with FPG or PGPG in the diabetic range (i.e FPG ≥ 126 mg/dL and PGPG ≥ 200 mg/dL were excluded from the study since they would require anti-diabetic medication or therapeutic lifestyle change, in addition to thyroxin treatment -thus introducing a confounding factor of impact of diabetes treatment on HbA 1c , while studying HbA 1c alterations with thyroxin replacement. Only patients with normal glucose values or patients with IFG/ IGT were thus included. The reason for choosing three months follow up was on account of the approximately 120 days lifespan of the RBCs in circulation (3, 4) .
Our study showed mild anaemia with a low reticulocyte count at baseline in concordance with other studies (12, 20) . In our patients, following thyroid hormone replacement, the haemoglobin and the reticulocyte count rose. Likewise Bashir and cols. (20) , in a retrospective study showed that as compared to a Hb of 10.73 ± 0.86 gm/dL in untreated primary hypothyroid patients it was 12.64 ± 1.33 in treated primary hypothyroid patients (p < 0.001).
Though there was a mean weight loss of approximately 3.5 kg from baseline following the correction of hypothyroidism, the plasma glucose values remained unaltered (Table 2 ). Further the proportion of patients with dysglycemic states IGT or IFG or prediabetes based on plasma glucose (either IGT and/or IFG) did not change. These findings are similar to what was observed by Kim and cols. (12) who showed that there were no changes observed in FPG or in 1,2 an hydroglycitol (an index of postprandial hyperglycemia) following the correction of hypothyroidism.
Despite the mean FPG and PGPG being normal, the mean HbA 1c at baseline was already in the prediabetes range. A significant proportion of patients had a false Kim and cols. (12) who showed that HbA 1c in 45 hypothyroid patients was higher than that in control subjects (5.54 ± 0.43% vs. 5.34 ± 0.31% in hypothyroid patients and controls respectively; p < 0.001), despite the lower level of plasma fasting glucose in the hypothyroid individuals. Christy and cols. (21) selected 30 hypothyroid (TSH > 14 mIU/L) non diabetic (FPG < 100 mg/dL) patients with normocytic normochromic anemia and compared these patients with 30 euthyroid non diabetic patients also with normocytic normochromic anemia. HbA 1c in the hypothyroid patients was 6.32 ± 0.75 % vs. 5.87 ± 0.46% in the euthyroid group, the difference being statistically significant. Despite all subjects in this study being euglycemic, the odds ratio for HbA 1c > 6.5% in hypothyroid patients with anemia was 3.16 in comparison to euthyroid persons.
Following correction of hypothyroidism and maintenance of the euthyroid state for up to 3 months, the initially elevated mean HbA 1c was found to fall to a normal value despite there being no change in the FPG and the PGPG. Similar findings were reported by Kim and cols. (12) in their 30 hypothyroid patients who were resumed on thyroxin replacement. In their study, HbA 1c fell from 5.57 ± 0.26% at baseline to 5.37 ± 0.32% 1 month after commencing thyroxin replacement; a magnitude of fall similar to that seen in our study.
Change in the HbA 1c cannot be attributed to the fall in the BMI as there was no significant association between these parameters on multiple linear regression. Moreover there is no mechanism by which the BMI can influence the HbA 1c other than through the level of glycemia, which has remained unaffected between baseline time point and post 3 months follow up.
Similar reduction of HbA 1c without attempting to control glucose has also been observed in patients with vitamin B 12 deficiency treated with vitamin B 12 or iron deficiency individuals treated with iron (7) or renal failure patients treated with erythropoietin (8) . In all these cases the fall in HbA 1c was attributed to the appearance of newly formed young RBCs in circulation. In our patients also, this process is reflected in the observed rise in the reticulocyte percentage. However there was no statistical association between the change in the HbA 1c and the change in the reticulocyte percentage or the hemoglobin. This may be due to the following reasons. Firstly, though the study is adequately powered to detect changes in HbA 1c between pre and post treatment time points, it may not be adequately powered to assess causal associations with changes in the reticulocyte percentage. Secondly the reticulocytes only represent the "youngest" red blood cells, but do not fully reflect the the entire population of "young" RBCs in circulation. There is currently no satisfactory method to study the average age of the RBCs in circulation at two different points in time, which would have been the ideal tool in this study.
In our study the diagnosis (based on HbA 1c ) of dysglycemia (HbA 1c ≥ 5.7%) made earlier was subsequently changed to euglycemia in nearly one third of the patients initially diagnosed as dysglycemia. Similar reduction was observed in the proportion of patients with the wrong diagnosis (based on HbA 1c ) of dysglycemia (i.e HbA 1c ≥ 5.7 despite normal FPG and PGPG) and diabetes mellitus. Thus a very small reduction in HbA 1c of only 0.2% nevertheless has a significant impact on the HbA 1c based diagnostic categorization of hypothyroid patients. This aspect has not been studied earlier.
To conclude, levels of HbA 1c are falsely elevated, out of proportion to the level of glycemia in patients with hypothyroidism. However it is lowered without any change in plasma glucose after correction of hypothyroidism. Consequently false diagnosis of dysglycemia may be made if HbA 1c alone is used for diagnosis in patients with overt hypothyroidism. Therefore in hypothyroid patients, reliance should be placed only on fasting plasma glucose or the oral glucose tolerance test (OGTT) to diagnose prediabetes or type 2 diabetes.
The study is limited by having only a small number of patients, a relatively short follow up duration of 3 months and by the absence of a control group. A larger study with a longer follow up may be of use to confirm our results.
